Currently, there are 392.10M common shares owned by the public and among those 386.48M shares have been available to trade.
The company’s stock has a 5-day price change of 5.51% and 16.26% over the past three months. DXCM shares are trading -24.55% year to date (YTD), with the 12-month market performance up to 12.60% higher. It has a 12-month low price of $57.52 and touched a high of $117.19 over the same period. DXCM has an average intraday trading volume of 4.03 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.95%, 9.38%, and 13.79% respectively.
Institutional ownership of Dexcom Inc (NASDAQ: DXCM) shares accounts for 93.56% of the company’s 392.10M shares outstanding.
It has a market capitalization of $34.34B and a beta (3y monthly) value of 1.46. The stock’s trailing 12-month PE ratio is 65.74, while the earnings-per-share (ttm) stands at $1.33. The company has a PEG of 2.74 and a Quick Ratio of 1.32 with the debt-to-equity ratio at 1.14. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.05% over the week and 2.48% over the month.
Analysts forecast that Dexcom Inc (DXCM) will achieve an EPS of 0.44 for the current quarter, 0.57 for the next quarter and 2.52 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.4 while analysts give the company a high EPS estimate of 0.4. Comparatively, EPS for the current quarter was 0.43 a year ago. Earnings per share for the fiscal year are expected to increase by 23.67%, and 25.37% over the next financial year. EPS should shrink at an annualized rate of 23.98% over the next five years, compared to 39.06% over the past 5-year period.
Looking at the support for the DXCM, a number of firms have released research notes about the stock. Truist stated their Buy rating for the stock in a research note on June 16, 2025, with the firm’s price target at $102. Goldman coverage for the Dexcom Inc (DXCM) stock in a research note released on May 30, 2025 offered a Buy rating with a price target of $104. Mizuho was of a view on April 10, 2025 that the stock is Outperform, while Redburn Atlantic gave the stock Buy rating on February 03, 2025, issuing a price target of $85- $115. Robert W. Baird on their part issued Outperform rating on January 16, 2025.
